Cramer's Morning Take: Bristol Meyers & Eli Lilly 1/16/25
Squawk on the Street
00:00
Intro
This chapter explores insights from market analyses presented at the JPMorgan Healthcare Conference, focusing on Bristol Myers as an undervalued stock with strong potential in treating major mental health conditions. The discussion highlights confidence in its future performance and its appeal as a key investment opportunity.
Transcript
Play full episode
